Anna Martínez-Cardús

Anna Martínez-Cardús

UNVERIFIED PROFILE

Are you Anna Martínez-Cardús?   Register this Author

Register author
Anna Martínez-Cardús

Anna Martínez-Cardús

Publications by authors named "Anna Martínez-Cardús"

Are you Anna Martínez-Cardús?   Register this Author

39Publications

1690Reads

48Profile Views

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.

Oncogene 2019 11 13;38(45):7106-7112. Epub 2019 Aug 13.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0936-xDOI Listing
November 2019

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.

Int J Mol Sci 2018 Oct 19;19(10). Epub 2018 Oct 19.

Medical Oncology Department, B-ARGO Group, Institut Català d'Oncologia Badalona, Carretera del Canyet s/n, 08916 Badalona, Spain.

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/19/10/3249
Publisher Site
http://dx.doi.org/10.3390/ijms19103249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214122PMC
October 2018

Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Nat Rev Clin Oncol 2017 Nov 4;14(11):682-694. Epub 2017 Jul 4.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda Gran Via 199-203, 08908 L'Hospitalet del Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.97DOI Listing
November 2017

The Epigenomic Revolution in Breast Cancer: From Single-Gene to Genome-Wide Next-Generation Approaches.

Am J Pathol 2017 Oct 19;187(10):2163-2174. Epub 2017 Jul 19.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain; Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain; Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2017.07.002DOI Listing
October 2017

Journal club: epigenetic profiling to classify cancer of unknown primary - Authors' reply.

Lancet Oncol 2017 03 2;18(3):e131. Epub 2017 Mar 2.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08908, Spain; Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona 08036, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30105-5DOI Listing
March 2017

Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer.

Gastroenterology 2016 11 10;151(5):961-972. Epub 2016 Aug 10.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain; Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2016.08.001DOI Listing
November 2016

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Lancet Oncol 2016 Oct 27;17(10):1386-1395. Epub 2016 Aug 27.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain; School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30297-2DOI Listing
October 2016

Resistant mechanisms to BRAF inhibitors in melanoma.

Ann Transl Med 2016 Jun;4(12):237

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2016.06.07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930524PMC
June 2016

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.

PLoS One 2015 8;10(5):e0123830. Epub 2015 May 8.

Translational research in digestive tumours group, Laboratory of Molecular Cancer Biology, Health Sciences Research Institute of the Germans Trias i Pujol Foundation (IGTP), Badalona, Spain; Medical Oncology Service, Catalan Institute of Oncology (ICO) University Hospital Germans Trias I Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123830PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425499PMC
February 2016

KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer.

Cancer Res 2015 Sep 24;75(18):3936-45. Epub 2015 Jul 24.

Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain. Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3702DOI Listing
September 2015

Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance.

Ann Transl Med 2015 Sep;3(15):209

1 Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain ; 2 Medical Oncology Service, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.06.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583598PMC
September 2015

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.

Mol Cancer Ther 2015 Aug 16;14(8):1767-76. Epub 2015 Jul 16.

Medical Oncology Service, Catalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Badalona, Barcelona, Catalonia, Spain. Health Sciences Research Institute of the Germans Trias i Pujol Foundation (IGTP). Badalona, Catalonia, Spain. Oncology Unit, Hospital CIMA Sanitas, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0636DOI Listing
August 2015

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Nat Med 2015 Jul 1;21(7):741-50. Epub 2015 Jun 1.

1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968631PMC
July 2015

A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition.

Cancer Res 2014 Oct 8;74(19):5608-19. Epub 2014 Aug 8.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat; Barcelona, Spain. Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain. Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3659DOI Listing
October 2014

Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray.

Epigenetics 2014 Jun 14;9(6):829-33. Epub 2014 Apr 14.

Cancer Epigenetics and Biology Program (PEBC); Bellvitge Biomedical Research Institute (IDIBELL); Barcelona, Catalonia, Spain; Department of Physiological Sciences II; School of Medicine; University of Barcelona; Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA); Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/epi.28790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065180PMC
June 2014

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect.

Nat Commun 2014 Apr 3;5:3608. Epub 2014 Apr 3.

1] Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, 08908 Catalonia, Spain [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, 08036 Barcelona, Spain [3] Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, 08010 Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms4608DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988805PMC
April 2014

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

J Natl Cancer Inst 2014 Jan 22;106(1):djt322. Epub 2013 Nov 22.

Affiliations of authors: Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain (CM, AM-C, FJC, ME); Medical Oncology Service, Catalan Institute of Oncology, Health Sciences Research Institute of the Germans Trias i Pujol Foundation, Barcelona, Spain (AM-C, EM-B, AA); Department of Medical Oncology (CS, RS) and Clinical Informatics Unit (VN-P), Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Pathology, Germans Trias i Pujol Foundation, Barcelona, Spain (EM); Department of Hematology and Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy (AS-B, AC, SS); Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain (EE, JT); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Barcelona, Spain (ME); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (ME).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906989PMC
January 2014

Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.

Med Oncol 2013 Mar 22;30(1):428. Epub 2013 Jan 22.

Medical Oncology Department, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-012-0428-0DOI Listing
March 2013

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.

Int J Cancer 2009 Jun;124(12):2905-10

Medical Oncology Service, Hospital Universitari Germans Trias i Pujol, Institut Català d'Oncologia, Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.24273DOI Listing
June 2009

A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines.

Mol Cancer Ther 2009 Apr;8(4):771-8

Medical Oncology Service, Hospital Universitari Germans Trias i Pujol, Institut Catala Oncologia, Badalona 08916, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0882DOI Listing
April 2009

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.

Mol Cancer Ther 2009 Jan;8(1):194-202

Medical Oncology Service, Institut Català Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona 08916, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0659DOI Listing
January 2009